Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;206(4):1241-1245.
doi: 10.1111/bjh.20024. Epub 2025 Feb 19.

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience

Richard J Kelly  1 , Austin G Kulasekararaj  2 , Louise M Arnold  1 , Catherine Barnfield  1 , Isla Storey  1 , Jessica Molyneux  1 , Nora L Youngs  1 , Joanna Large  2 , Lindsay Mitchell  3 , Sateesh K Nagumantry  4 , Shreyans Gandhi  2 , Roochi Trikha  2 , Abraham Varghese  1 , Talha Munir  1 , Petra Muus  1 , Morag Griffin  1
Affiliations

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience

Richard J Kelly et al. Br J Haematol. 2025 Apr.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–1258.
    1. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985–4996.
    1. Hillmen P, Young N, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–1243.
    1. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–1847.
    1. Lee JW, de Fontbrune FS, Lee LWL, Pessoa V, Gualandro S, Füreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133:530–539.

LinkOut - more resources